SCHEDULE: BlackRock Reports 5.4% Stake in ADC Therapeutics

BlackRock, Inc. has disclosed beneficial ownership of 5.4% of ADC Therapeutics SA's common stock as of June 30, 2026.

Summary

• BlackRock, Inc. has filed a Schedule 13G, indicating beneficial ownership of 6,857,815 shares of ADC Therapeutics SA common stock.
• This represents 5.4% of the total outstanding shares of the issuer.
• The filing is made in accordance with Rule 13d-1(b) and BlackRock, Inc. is classified as a holding company.
• The reporting period for this filing is as of June 30, 2026.
• BlackRock, Inc. has sole voting power over 6,765,332 shares and sole dispositive power over 6,857,815 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports an existing institutional ownership stake without providing new operational or financial performance data for the issuer.

Positives

• BlackRock, a significant institutional investor, holds a substantial stake in ADC Therapeutics SA, which can be viewed as a positive signal of confidence.
• The filing indicates clear and sole dispositive power over the reported shares, suggesting decisive control over investment decisions.

Negatives

• The filing does not contain any negative financial results or operational challenges for ADC Therapeutics SA.

Risks

• The filing does not explicitly mention any risks related to ADC Therapeutics SA's operations or market position.

Future Outlook

The filing does not contain any forward-looking statements or guidance from ADC Therapeutics SA. It solely reports BlackRock's ownership stake.

Management Comments

• BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant holdings by major asset managers like BlackRock in biotechnology companies are common, reflecting active portfolio management and strategic investment in the sector. This filing indicates BlackRock's ongoing interest in ADC Therapeutics SA.

Stakeholder Impact

• Shareholders of ADC Therapeutics SA may view BlackRock's substantial stake as a sign of institutional support, potentially influencing market perception.
• The filing confirms BlackRock's role as a significant investor, which could impact future corporate actions or strategic decisions involving the company.

Next Steps

• BlackRock, Inc. will continue to hold or manage its stake in ADC Therapeutics SA.
• Further filings may be required if BlackRock's ownership stake changes significantly.

Key Dates

Keywords

ADC Therapeutics SA, BlackRock, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, Shareholder